# Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)

> **NCT06779695** · — · ACTIVE_NOT_RECRUITING · sponsor: **Korea University Anam Hospital** · enrollment: 2000 (estimated)

## Conditions studied

- Atrial Fibrillation (AF)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06779695
- **Lead sponsor:** Korea University Anam Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-21
- **Primary completion:** 2028-09-30
- **Final completion:** 2031-12-31
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2025-01-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06779695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06779695, "Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06779695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*